000			nab a22 7a 4500
999			_c17255 _d17255
003			PC17255
005			20230223121327.0
008			230223b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91172 _aDíaz de Atauri Rodríguez de los Ríos, María Josefa _eNeumología
245	0	0	_aPrecision Medicine in Patients With Resistant Hypertension and Obstructive Sleep Apnea: Blood Pressure Response to Continuous Positive Airway Pressure Treatment. _h[artículo]
260			_bJournal of the American College of Cardiology, _c2015
300			_a66(9):1023-32.
500			_aFormato Vancouver: Sánchez de la Torre M, Khalyfa A, Sánchez de la Torre A, Martínez Alonso M, Martínez-García MÁ, Barceló A et al; Spanish Sleep Network. Precision Medicine in Patients With Resistant Hypertension and Obstructive Sleep Apnea: Blood Pressure Response to Continuous Positive Airway Pressure Treatment. J Am Coll Cardiol. 2015 Sep 1;66(9):1023-32.
501			_aPMID: 26314530
504			_aContiene 41 referencias
520			_aBackground: In patients with resistant hypertension (RH) and obstructive sleep apnea (OSA), the blood pressure response to continuous positive airway pressure (CPAP) treatment is highly variable and could be associated with differential micro-ribonucleic acid (miRNA) profiles. Currently, no available methods exist to identify patients who will respond favorably to CPAP treatment. Objectives: The aim of this study was to identify plasma miRNA profiles that predict blood pressure responses to CPAP treatment. Methods: Cardiovascular system-focused circulating miRNA expression was evaluated in plasma samples using an 84-miRNA array among patients with RH and OSA at baseline and after 3 months of adherent CPAP use. Pathway analysis and miRNA target gene enrichment were performed in silico. Plasma levels of peptides and hormones related to cardiovascular function were also measured. Results: The OSA responder group exhibited blood pressure decreases exceeding the observed median (>4.5 mm Hg) after CPAP, which were not present in the nonresponder group (≤4.5 mm Hg) (p < 0.01). Three miRNAs provided a discriminatory predictive model for such a favorable blood pressure response to CPAP (area under the curve: 0.92; p = 0.01). Additionally, CPAP treatment significantly altered a total of 47 plasma miRNAs and decreased aldosterone-to-renin ratios in the responder group (p = 0.016) but not in the nonresponder group. Conclusions: A singular pre-CPAP treatment cluster of 3 plasma miRNAs predicts blood pressure responses to CPAP treatment in patients with RH and OSA. CPAP treatment is accompanied by changes in cardiovascular system-related miRNAs that may potentially influence the risk for cardiovascular disease among patients with OSA and RH.
710			_988 _aServicio de Neumología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17255.pdf _ySolicitar documento
942			_2ddc _cART _n0